Muenchener Rueckver Ges Stock Earnings Reports

Munich Re reported a strong start to 2026 with a Q1 net result of EUR 1.7bn. Underwriting across segments was broadly robust: Life & Health Reinsurance produced a strong technical result (EUR 500m), P&C Reinsurance delivered an excellent normalized combined ratio (80.3%) supported by very low major losses and discounting benefits, and Global Specialty Insurance outperformed full‑year guidance (combined ratio 83.7%). ERGO (primary insurance) posted a pleasing net result (EUR 235m) with improved Life & Health technicals in Germany and solid international performance despite some one‑offs. Investment returns were weak relative to guidance (return on investments 2.9%) due to marked‑to‑market volatility in bonds and equities, but reinvestment yield improved to 4.2%, and diversification (alternatives/commodities) helped limit downside. Key renewal dynamics: competitive pricing persists (notably in nat‑cat), April renewals saw an 18.5% reduction in renewed treaty volume (on a small book) as Munich Re prioritized portfolio quality and disciplined underwriting; outlier (large loss) expectation increased from 17% to 18% (now split ~14.5% nat‑cat, 3.5% man‑made). Management reaffirmed the 2026 net result outlook of EUR 6.3bn but acknowledged that achieving reinsurance revenue guidance of EUR 40bn is more challenging and will depend on deal flow (pipeline) and some one‑off premium adjustments that depressed Q1. Capital position remains strong (Solvency II ~292%); management intends to stick to previously communicated capital return philosophy while assessing full‑year distributable results before making further buyback decisions. Risks and catalysts for investors: continued capital market volatility (investment result), nat‑cat and man‑made large losses (higher outlier expectation), competitive pricing pressure in reinsurance renewals (impacting top line), and the timing/realization of large Life & Health transactions that could help deliver the revenue target.